In the latest session, Health Catalyst Inc (NASDAQ: HCAT) closed at $6.96 down -4.40% from its previous closing price of $7.28. In other words, the price has decreased by -$0.32 from its previous closing price. On the day, 664873 shares were traded.
Ratios:
For a deeper understanding of Health Catalyst Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.39 and its Current Ratio is at 4.39. In the meantime, Its Debt-to-Equity ratio is 0.68 whereas as Long-Term Debt/Eq ratio is at 0.67.
On January 03, 2024, Barclays started tracking the stock assigning a Overweight rating and target price of $14.
JP Morgan Upgraded its Neutral to Overweight on December 13, 2023, whereas the target price for the stock was revised from $14 to $11.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 15 ’24 when Llewelyn Linda sold 2,005 shares for $7.80 per share. The transaction valued at 15,648 led to the insider holds 128,231 shares of the business.
Burton Daniel D. bought 26,200 shares of HCAT for $204,525 on Feb 27 ’24. The Chief Executive Officer now owns 1,172,623 shares after completing the transaction at $7.81 per share. On Feb 15 ’24, another insider, Llewelyn Linda, who serves as the Chief People Officer of the company, sold 3,262 shares for $9.77 each. As a result, the insider received 31,855 and left with 64,786 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HCAT now has a Market Capitalization of 407.01M and an Enterprise Value of 338.35M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.38 while its Price-to-Book (P/B) ratio in mrq is 1.11. Its current Enterprise Value per Revenue stands at 1.14 whereas that against EBITDA is -4.96.
Stock Price History:
Over the past 52 weeks, HCAT has reached a high of $14.37, while it has fallen to a 52-week low of $6.60. The 50-Day Moving Average of the stock is 8.78, while the 200-Day Moving Average is calculated to be 9.77.
Shares Statistics:
For the past three months, HCAT has traded an average of 611.13K shares per day and 483.07k over the past ten days. A total of 58.30M shares are outstanding, with a floating share count of 55.71M. Insiders hold about 4.87% of the company’s shares, while institutions hold 86.80% stake in the company. Shares short for HCAT as of Mar 15, 2024 were 1.82M with a Short Ratio of 2.98, compared to 1.43M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.11% and a Short% of Float of 3.55%.
Earnings Estimates
There are 14 different market analysts currently analyzing its stock. On average, analysts expect EPS of $0.03 for the current quarter, with a high estimate of $0.06 and a low estimate of -$0.06, while EPS last year was $0.05. The consensus estimate for the next quarter is $0.08, with high estimates of $0.12 and low estimates of $0.01.
Analysts are recommending an EPS of between $0.45 and -$0.01 for the fiscal current year, implying an average EPS of $0.32. EPS for the following year is $0.5, with 15 analysts recommending between $0.65 and $0.35.
Revenue Estimates
A total of 16 analysts believe the company’s revenue will be $75.08M this quarter.It ranges from a high estimate of $79.6M to a low estimate of $74.05M. As of the current estimate, Health Catalyst Inc’s year-ago sales were $71.24M, an estimated increase of 5.40% from the year-ago figure.
A total of 17 analysts have provided revenue estimates for HCAT’s current fiscal year. The highest revenue estimate was $331M, while the lowest revenue estimate was $306.03M, resulting in an average revenue estimate of $309.89M. In the same quarter a year ago, actual revenue was $295.94M, up 4.70% from the average estimate. Based on 17 analysts’ estimates, the company’s revenue will be $345.24M in the next fiscal year. The high estimate is $353M and the low estimate is $337.8M. The average revenue growth estimate for next year is up 11.40% from the average revenue estimate for this year.
